The international surgical journal with global reach

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer 2020; 126: 1175-1182.

Published: 17th November 2020

Authors: Papakonstantinou A, Matikas A, Bengtsson NO, Malmstrom P, Hedayati E, Steger G et al.

Conclusion

In this study that included 342 women, relapse-free survival was not significantly improved by the addition of trastuzumab: hazard ratio 0.68, 95 per cent confidence interval 0.37 to 1.27.

Pubmed Link